Articles From: Intercontinental Exchange to Sell Remaining Shares in Euronext to Interim Data from Proof-of-Concept Study of Merck’s Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with a Nucleotide Inhibitor (C-SWIFT study) Presented at The Liver Meeting®


Intercontinental Exchange (NYSE: ICE), the leading global network of exchanges and clearing houses, announced today its intention to sell approximately 4.2 million shares in Euronext N.V., representing approximately 6% of Euronext’s share capital, by way of an accelerated book-building to institutional investors.
Sign-up for Intercontinental Exchange to Sell Remaining Shares in Euronext investment picks
2014/12/1
http://media.marketwire.com/attachments/201412/294073_icor_03.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1162347&ProfileId=051205&sourceType=1 DELRAY BEACH, FL --
Sign-up for InterCore's Driver Alertness Detection System(TM) Now Available investment picks
2014/12/1
InterCore, Inc. (OTC Pink:ICOR) ("InterCore") announces that DADS TM —the network-based D river A lertness D etection S ystem TM —is now available for purchase at DADS.SRGINT.com .
Sign-up for InterCore’s Driver Alertness Detection System™ Now Available investment picks
WILMINGTON, Del., Nov.
Sign-up for InterDigital Adds Former Nokia Executive Kai Oistamo to Board of Directors investment picks
WILMINGTON, Del., Oct.
Sign-up for InterDigital Announces Date for Third Quarter 2014 Financial Results investment picks
WILMINGTON, Del., Dec.
Sign-up for InterDigital Demonstrates M2M Standards Research at oneM2M Showcase Event investment picks
WILMINGTON, Del., Nov.
Sign-up for InterDigital Issues Revenue Guidance for Fourth Quarter 2014 investment picks
WILMINGTON, Del., Oct.
Sign-up for InterDigital Prevails Over ZTE in Delaware District Court investment picks
WILMINGTON, Del., Dec.
Sign-up for InterDigital Principal Engineer Named IEEE Fellow investment picks
WILMINGTON, Del., Oct.
Sign-up for InterDigital Third Quarter 2014 Financial Results Driven by 57% Increase in Recurring Revenue investment picks
WILMINGTON, Del., Sept.
Sign-up for InterDigital to Discuss the Future of Wireless Networks at TC3 investment picks
WILMINGTON, Del., Nov.
Sign-up for InterDigital to Present at Barclays & NASDAQ OMX Conferences investment picks
WILMINGTON, Del., Sept.
Sign-up for InterDigital's Board of Directors Declares Regular Quarterly Cash Dividend investment picks
WILMINGTON, Del., Dec.
Sign-up for InterDigital's Board of Directors Declares Regular Quarterly Cash Dividend investment picks
WILMINGTON, Del., Nov.
Sign-up for InterDigital's Innovation Partners Expands Its Relationship With McGill University in Canada investment picks
ATLANTA , Oct.
Sign-up for Interface Declares Regular Quarterly Dividend investment picks
ATLANTA , Oct.
Sign-up for Interface Reports Third Quarter 2014 Results investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0977599001&sourceType=1 http://media3.marketwire.com/logos/20131106-200if.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Interfor Reports Strong Results in Q3'14 investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0971862001&sourceType=1 http://media3.marketwire.com/logos/20131106-200if.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Interfor to Announce Third Quarter Results on November 6, 2014 investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0973383001&sourceType=1 http://media3.marketwire.com/logos/20131106-200if.jpg http://media3.marketwire.com/logos/20141016-ILIM%20200.jpg http://www.marketwire.com/library/20141016-Timber300.jpg Interfor will market Ilim Timber's European lumber products in North America VANCOUVER, BRITISH COLUMBIA --
Sign-up for Interfor to Market Ilim Timber's Products in North America investment picks
2014/10/6
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1149643&ProfileId=051205&sourceType=1 ATLANTA, GA --
Sign-up for Interglobe Entertainment Group LLC Selects Findit's Campaign Management Platform to Promote Artist Anselmo Ralph investment picks
DUBLIN , October 20, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) announces that James Bowling , Interim Chief Financial Officer (CFO), has notified the Board of Directors of his decision to step down from his current role to pursue a new career opportunity as CFO of Severn Trent plc.
Sign-up for Interim Chief Financial Officer James Bowling to Step Down investment picks
93% (13/14) of evaluable CLL patients treated at dose levels ≥ 800mg of original formulation or any dose of the micronized formulation achieved a > 50% reduction in nodal size (a nodal PR) and 50% (7/14) achieved a partial response per iwCLL (Hallek 2008) criteria 100% (6/6) of CLL and iNHL patients achieving TGR-1202 drug concentrations above 4,000ng/ml responded at the first or second efficacy assessment with at least a nodal PR for CLL or PR for iNHL; Expansion cohorts now open at 800mg QD for CLL and 1200mg QD for iNHL, the dose level that appears to provide patients (3/3) with drug concentrations > 4,000ng/ml No drug related hepatic toxicity or colitis observed with 55 patients treated to date and median time on study of approximately 6 months and some patients on study for over 1.5 years TGR-1202 has been well-tolerated with no dose-related trends in adverse events observed and no MTD reached to date, dose escalation continues now at 1800mg QD SAN
Sign-up for Interim Data From Phase 1 Dose Escalation Clinical Trial of TGR-1202, the Once-Daily PI3K Delta Inhibitor, Demonstrates Significant Clinical Activity and Lack of Hepatic Toxicity in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir (MK-5172/MK-8742, MK-5172A), the company’s investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide (NS5B) inhibitor for the treatment of chronic hepatitis C virus (HCV) infection.
Sign-up for Interim Data from Proof-of-Concept Study of Merck’s Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with a Nucleotide Inhibitor (C-SWIFT study) Presented at The Liver Meeting® investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Intercontinental Exchange to Sell Remaining Shares in Euronext to Interim Data from Proof-of-Concept Study of Merck’s Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with a Nucleotide Inhibitor (C-SWIFT study) Presented at The Liver Meeting®
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent